Benzinga · Sep 10, 2026
Keros Therapeutics Files Prospectus For Offering $350M Mixed Shelf; May Offer $100M Common Shares Under Sales Agreement With Leering Partners
SEC.
KR
NASDAQ · KROS
Keros Therapeutics, Inc.
Healthcare · Biotechnology
$11.28
Down-$0.09 (-0.80%)
Updated Sep 30, 2026, 12:52 AM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 878.88M
- P/E ratio
- 13.67
- Dividend yield
- 0.00%
- 52-week range
- $9.69 – $12.65
- Volume
- 208.64K
- Avg. volume
- 987.56K
Price performance · KROS
KROS price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
KROS closed at $11.28 after 19 trading sessions, up 1.90% for the selected period.
- Last close
- $11.28
- Period change
- +1.90%
- Period low
- $10.74
- Period high
- $11.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $11.33 | $11.41 | $10.925 | $11.28 | 208.64K |
| Sep 25, 2026 | $11.54 | $11.70 | $11.285 | $11.62 | 216.07K |
| Sep 24, 2026 | $11.60 | $11.60 | $10.97 | $11.55 | 284.44K |
| Sep 23, 2026 | $11.68 | $11.82 | $11.47 | $11.63 | 157.54K |
| Sep 22, 2026 | $11.54 | $12.05 | $11.43 | $11.73 | 189.82K |
| Sep 21, 2026 | $11.31 | $11.60 | $11.08 | $11.48 | 120.72K |
| Sep 18, 2026 | $11.32 | $11.40 | $11.10 | $11.19 | 302.48K |
| Sep 17, 2026 | $10.87 | $11.39 | $10.83 | $11.36 | 274.09K |
| Sep 16, 2026 | $11.23 | $11.23 | $10.70 | $10.74 | 273.99K |
| Sep 15, 2026 | $11.16 | $11.21 | $10.72 | $11.17 | 199.98K |
| Sep 14, 2026 | $11.10 | $11.34 | $10.98 | $11.21 | 342.16K |
| Sep 11, 2026 | $11.25 | $11.34 | $11.025 | $11.08 | 143.83K |
| Sep 10, 2026 | $11.16 | $11.20 | $11.00 | $11.17 | 128.79K |
| Sep 9, 2026 | $11.475 | $11.82 | $11.21 | $11.31 | 188.51K |
| Sep 8, 2026 | $11.16 | $11.31 | $10.98 | $11.17 | 73.05K |
| Sep 4, 2026 | $11.03 | $11.40 | $11.02 | $11.32 | 65.64K |
| Sep 3, 2026 | $11.27 | $11.32 | $10.9173 | $11.11 | 148.71K |
| Sep 2, 2026 | $11.07 | $11.49 | $10.97 | $11.23 | 97.97K |
| Sep 1, 2026 | $11.02 | $11.125 | $10.83 | $11.07 | 96.24K |
Latest KROS news
The latest Smart Investors Daily articles mentioning KROS.
Stock researchCompany · Overview
Company
OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials
Market Activity
OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment
Research & News
KROS research
Overview
Company profile and research snapshot.
Company profile
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $102.60
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Leerink Partners | Outperform | — |
| Aug 4, 2026 | Wells Fargo | Overweight | — |
| Mar 5, 2026 | Wells Fargo | Overweight | — |
| Nov 28, 2025 | B of A Securities | Neutral | — |
| Nov 12, 2025 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company’s co
Benzinga · Sep 8, 2026
Keros Therapeutics Reveals $5M Share Repurchase Authorization
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of
Yahoo · Sep 2, 2026
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
